Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
WARREN, N.J. - Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced Friday that the World Intellectual Property Organization (WIPO) has published its international patent application for technology that uses machine learning to predict immunologically active peptides.
The patent publication (WO 2025/129197), titled "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models," covers technology developed by Tevogen.AI that utilizes algorithms powered by Microsoft (NASDAQ:MSFT) and Databricks to identify peptides that interact strongly with the immune system.
According to the company’s press release statement, the technology aims to address limitations in traditional peptide identification methods by efficiently screening potential peptides, eliminating ineffective candidates, and continuously refining predictions with real-world data.
The company states the technology considers human genetic diversity factors including age, sex, race, and ethnicity that are often overlooked in conventional approaches.
"I’m pleased with Tevogen.AI’s continued progress in strategically harnessing artificial intelligence in support of our cell therapy development," said Dr. Ryan Saadi, Founder and CEO of Tevogen.
Identifying immunologically active peptides is important in developing targeted therapies for various diseases, including cancers and infectious diseases.
Tevogen Bio is focused on developing T cell therapies, with the company indicating that AI technology could potentially accelerate discovery, shorten development timelines, and reduce costs in its therapeutic development process.
In other recent news, Microsoft has been the focus of several significant developments. BofA Securities has raised its price target for Microsoft to $585, citing strong performance in its Azure cloud platform, which is expected to see a 35.5% year-over-year growth. This upward revision reflects confidence in Microsoft’s ability to maintain growth despite economic challenges. Meanwhile, TD Cowen also increased its price target for Microsoft to $580, highlighting the company’s advantageous position in the AI sector and improved capacity constraints in Azure.
In a separate development, Microsoft is collaborating with Denmark’s EIFO and the Novo Nordisk Foundation to establish QuNorth, a new initiative that will house the world’s most powerful quantum computer. The project, which involves a partnership with Atom Computing, is expected to be operational by early 2027. Additionally, Microsoft has entered into agreements with Idaho National Laboratory to provide AI technologies for nuclear permitting, as part of a broader trend of tech companies partnering with nuclear entities. These recent activities underscore Microsoft’s continued expansion and strategic positioning in cutting-edge technology sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.